Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Gemfibrozil tablets, USP 600mg (Cipla)
Section 19A approved medicine
(Approval lapsed) Gemfibrozil tablets, USP 600mg (Cipla)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd 20 605 457 430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
LIPIGEM gemfibrozil 600mg tablet bottle AUST R 61430
Indication(s)
Gemfibrozil is indicated as an adjunct to diet and other therapeutic measures for:
- Severe hypertriglyceridaemia (Type IV and V) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.
- Dyslipidaemia associated with diabetes.
- Reduction of risk of coronary heart disease in patients with Type IIa and IIb hypercholesterolaemia.